Dimitri Krainc

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4653414/publications.pdf

Version: 2024-02-01

99 papers	19,881 citations	50276 46 h-index	36028 97 g-index
105 all docs	105 docs citations	105 times ranked	31622 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Gaucher Disease Glucocerebrosidase and Î±-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell, 2011, 146, 37-52.	28.9	1,097
4	Transcriptional Repression of PGC-1Î± by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell, 2006, 127, 59-69.	28.9	912
5	Î±-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nature Medicine, 2017, 23, 1-13.	30.7	688
6	Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease. Science, 2002, 296, 2238-2243.	12.6	638
7	Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. Cell Stem Cell, 2013, 13, 691-705.	11.1	613
8	Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinsonâ€™s disease. Science, 2017, 357, 1255-1261.	12.6	600
9	Mitochondriaâ€“lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis. Nature, 2018, 554, 382-386.	27.8	564
10	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	12.4	444
11	Identification and Rescue of Î±-Synuclein Toxicity in Parkinson Patientâ€“Derived Neurons. Science, 2013, 342, 983-987.	12.6	416
12	Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinsonâ€™s Disease. Cell Stem Cell, 2016, 19, 709-724.	11.1	371
13	Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation. Cell, 2009, 137, 60-72.	28.9	367
14	Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. Journal of Neuroscience, 2011, 31, 5970-5976.	3.6	348
15	Î±-Synucleinâ€“induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1931-1936.	7.1	292
16	Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, Î±-Synuclein Accumulation, and Neurotoxicity. Journal of Neuroscience, 2012, 32, 4240-4246.	3.6	245
17	Activation of Â-Glucocerebrosidase Reduces Pathological Â-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Journal of Neuroscience, 2016, 36, 7693-7706.	3.6	220
18	Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinsonâ€™s Disease. Trends in Neurosciences, 2019, 42, 140-149.	8.6	206

#	Article	IF	Citations
19	Regulation and Function of Mitochondriaâ€“Lysosome Membrane Contact Sites in Cellular Homeostasis. Trends in Cell Biology, 2019, 29, 500-513.	7.9	203
20	Phosphatase and Tensin Homolog (PTEN)-induced Putative Kinase 1 (PINK1)-dependent Ubiquitination of Endogenous Parkin Attenuates Mitophagy. Journal of Biological Chemistry, 2013, 288, 2223-2237.	3.4	199
21	Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and Î±-Synuclein Accumulation. Stem Cell Reports, 2016, 7, 664-677.	4.8	164
22	Mitochondria-lysosome contacts regulate mitochondrial Ca ²⁺ dynamics via lysosomal TRPML1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19266-19275.	7.1	164
23	ATP13A2/PARK9 Regulates Secretion of Exosomes and Î±-Synuclein. Journal of Neuroscience, 2014, 34, 15281-15287.	3.6	148
24	Identification of TMEM230 mutations in familial Parkinson's disease. Nature Genetics, 2016, 48, 733-739.	21.4	146
25	Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Human Molecular Genetics, 2014, 23, 2791-2801.	2.9	137
26	LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinsonâ€™s disease patients. Nature Communications, 2019, 10, 5570.	12.8	131
27	Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited Î±-synuclein accumulation and age-dependent sensorimotor deficits. Human Molecular Genetics, 2013, 22, 2067-2082.	2.9	124
28	Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway. Journal of Neuroscience, 2016, 36, 2425-2437.	3.6	115
29	LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5576-5581.	7.1	115
30	LIMP-2 expression is critical for Î²-glucocerebrosidase activity and Î±-synuclein clearance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15573-15578.	7.1	109
31	Pathogenic effects of novel mutations in the Pâ€type ATPase ATP13A2 (PARK9) causing Kuforâ€Rakeb syndrome, a form of earlyâ€onset parkinsonism. Human Mutation, 2011, 32, 956-964.	2.5	105
32	Recessive mutations in VPS13D cause childhood onset movement disorders. Annals of Neurology, 2018, 83, 1089-1095.	5.3	104
33	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Human Molecular Genetics, 2017, 26, 4861-4872.	2.9	100
34	Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinsonâ€™s disease. Nature Communications, 2021, 12, 1807.	12.8	99
35	Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nature Neuroscience, 2020, 23, 15-20.	14.8	97
36	Increased Lysosomal Exocytosis Induced by Lysosomal Ca²⁺ Channel Agonists Protects Human Dopaminergic Neurons from Î±-Synuclein Toxicity. Journal of Neuroscience, 2019, 39, 5760-5772.	3.6	93

#	Article	IF	Citations
37	The Glycolytic Enzyme, GPI, Is a Functionally Conserved Modifier of Dopaminergic Neurodegeneration in Parkinsonâ€™s Models. Cell Metabolism, 2014, 20, 145-157.	16.2	82
38	Molecular mechanisms of Î±-synuclein and GBA1 in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 51-60.	2.9	77
39	A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	12.4	77
40	Identification of novel ATP13A2 interactors and their role in Î±-synuclein misfolding and toxicity. Human Molecular Genetics, 2012, 21, 3785-3794.	2.9	66
41	Mutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway. Journal of Neuroscience, 2017, 37, 9000-9012.	3.6	64
42	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. Movement Disorders, 2019, 34, 1406-1422.	3.9	62
43	Lysosomal Regulation of Inter-mitochondrial Contact Fate and Motility in Charcot-Marie-Tooth Type 2. Developmental Cell, 2019, 50, 339-354.e4.	7.0	59
44	Astrocytes Protect Human Dopaminergic Neurons from Î±-Synuclein Accumulation and Propagation. Journal of Neuroscience, 2020, 40, 8618-8628.	3.6	57
45	Acid ceramidase inhibition ameliorates Î±-synuclein accumulation upon loss of GBA1 function. Human Molecular Genetics, 2018, 27, 1972-1988.	2.9	53
46	Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration. Neurotherapeutics, 2019, 16, 611-634.	4.4	52
47	Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. Brain, 2018, 141, 3052-3064.	7.6	51
48	Inhibition of PIP4KÎ³ ameliorates the pathological effects of mutant huntingtin protein. ELife, 2017, 6, .	6.0	49
49	Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Human Molecular Genetics, 2020, 29, 716-726.	2.9	48
50	Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders, 2016, 31, 1610-1618.	3.9	47
51	Characterization of the complex formed by Î²-glucocerebrosidase and the lysosomal integral membrane protein type-2. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3791-3796.	7.1	45
52	Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies. Nature Communications, 2017, 8, 1908.	12.8	43
53	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 580634.	3.7	40
54	Clearance of Mutant Proteins as a Therapeutic Target in Neurodegenerative Diseases. Archives of Neurology, 2010, 67, 388-92.	4.5	39

#	Article	IF	Citations
55	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences, 2016, 73, 3205-3215.	5.4	37
56	Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Movement Disorders, 2019, 34, 614-624.	3.9	37
57	Gelator Length Precisely Tunes Supramolecular Hydrogel Stiffness and Neuronal Phenotype in 3D Culture. ACS Biomaterials Science and Engineering, 2020, 6, 1196-1207.	5.2	36
58	Assessing the relationship between monoallelic PRKN mutations and Parkinsonâ€™s risk. Human Molecular Genetics, 2021, 30, 78-86.	2.9	36
59	The Parkinsonâ€™s disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics, 2017, 26, ddw413.	2.9	35
60	Î²-Glucocerebrosidase Modulators Promote Dimerization of Î²-Glucocerebrosidase and Reveal an Allosteric Binding Site. Journal of the American Chemical Society, 2018, 140, 5914-5924.	13.7	29
61	Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence. Analytical Chemistry, 2016, 88, 2399-2405.	6.5	26
62	Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease. Neurology, 2022, 99, .	1.1	25
63	A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinsonâ€™s disease. Science Translational Medicine, 2020, 12, .	12.4	24
64	Lysosomal Proteins as a Therapeutic Target in Neurodegeneration. Annual Review of Medicine, 2017, 68, 445-458.	12.2	23
65	Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. Movement Disorders, 2021, 36, 2719-2730.	3.9	22
66	Organoid and pluripotent stem cells in Parkinsonâ€™s disease modeling: an expert view on their value to drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 427-441.	5.0	21
67	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
68	Micropatterning Facilitates the Longâ€Term Growth and Analysis of iPSCâ€Derived Individual Human Neurons and Neuronal Networks. Advanced Healthcare Materials, 2016, 5, 1894-1903.	7.6	18
69	Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. Journal of Clinical Investigation, 2021, 131, .	8.2	18
70	Development of targeted therapies for Parkinson's disease and related synucleinopathies. Journal of Lipid Research, 2014, 55, 1996-2003.	4.2	17
71	Design and Synthesis of Potent Quinazolines as Selective Î²-Glucocerebrosidase Modulators. Journal of Medicinal Chemistry, 2016, 59, 8508-8520.	6.4	16
72	Conversion of Quinazoline Modulators from Inhibitors to Activators of Î²-Glucocerebrosidase. Journal of Medicinal Chemistry, 2019, 62, 1218-1230.	6.4	16

#	Article	IF	Citations
73	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
74	<scp>MED27</scp> Variants Cause Developmental Delay, Dystonia, and Cerebellar Hypoplasia. Annals of Neurology, 2021, 89, 828-833.	5.3	14
75	Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological Î±-synuclein spread in the prodromal preformed fibrils model in young mice. Neurobiology of Disease, 2021, 159, 105513.	4.4	14
76	A PDE10A de novo mutation causes childhoodâ€onset chorea with diurnal fluctuations. Movement Disorders, 2017, 32, 1646-1647.	3.9	13
77	BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. PLoS ONE, 2018, 13, e0200344.	2.5	13
78	The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. Neurobiology of Disease, 2019, 132, 104545.	4.4	13
79	Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy. Molecular Neurodegeneration, 2021, 16, 12.	10.8	13
80	Dysregulation of organelle membrane contact sites in neurological diseases. Neuron, 2022, 110, 2386-2408.	8.1	12
81	Functional assays for the assessment of the pathogenicity of variants in GOSR2, an ER-to-Golgi SNARE involved in progressive myoclonus epilepsies. DMM Disease Models and Mechanisms, 2017, 10, 1391-1398.	2.4	11
82	Fluctuations in cell density alter protein markers of multiple cellular compartments, confounding experimental outcomes. PLoS ONE, 2019, 14, e0211727.	2.5	11
83	Lysosomal ceramides regulate cathepsin B-mediated processing of saposin C and glucocerebrosidase activity. Human Molecular Genetics, 2022, 31, 2424-2437.	2.9	11
84	Identification of ASCL1 as a determinant for human iPSC-derived dopaminergic neurons. Scientific Reports, 2021, 11, 22257.	3.3	10
85	Challenges to neurology residency education in today's health care environment. Annals of Neurology, 2016, 80, 315-320.	5.3	9
86	Long-term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease. JAMA - Journal of the American Medical Association, 2014, 311, 617.	7.4	8
87	Alzheimer GeneAPOEÎµ4 Linked to Brain Development in Infants. JAMA - Journal of the American Medical Association, 2014, 311, 298.	7.4	8
88	Pharmacological Upregulation of PGC1Î± in Oligodendrocytes: Implications for Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 101-105.	1.9	7
89	Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinsonâ€™s disease models. JCI Insight, 2021, 6, .	5.0	6
90	Untangling alpha synuclein fibrils by graphene quantum dots. Movement Disorders, 2018, 33, 1673-1673.	3.9	4

#	Article	IF	Citations
91	Modeling Brain Pathology of <scp>Niemannâ€Pick</scp> Disease Type C Using Patientâ€Derived Neurons. Movement Disorders, 2021, 36, 1022-1027.	3.9	4
92	Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry, 2021, 65, 873-883.	4.7	4
93	Mutant Huntingtin Secretion in Neuro2A Cells and Rat Primary Cortical Neurons. Bio-protocol, 2018, 8, .	0.4	4
94	Replication assessment of NUS1 variants in Parkinson's disease. Neurobiology of Aging, 2021, 101, 300.e1-300.e3.	3.1	3
95	Translating new research findings into clinical practice. Nature Reviews Neurology, 2012, 8, 65-66.	10.1	2
96	Transcriptional Abnormalities in Huntington's Disease. , 2006, , 417-440.		1
97	Human Neuron Cultures: Micropatterning Facilitates the Longâ€Term Growth and Analysis of iPSCâ€Derived Individual Human Neurons and Neuronal Networks (Adv. Healthcare Mater. 15/2016). Advanced Healthcare Materials, 2016, 5, 1893-1893.	7.6	0
98	High priority publications on Parkinson's disease in 2017. Lancet Neurology, The, 2018, 17, 8-10.	10.2	0
99	Novel Approach to Tracking Mutant Huntingtin in Biosamples. Trends in Molecular Medicine, 2018, 24, 978-981.	6.7	0